Source comparison
GHRP-2 Acetate vs Tesamorelin: Which Peptide Wins?
A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that tesamorelin reduced visceral adipose tissue (VAT) by 15.2% over 26 weeks in HIV-lipodystrophy patients. A result attributable to its selective GHRH receptor agonism rather
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that tesamorelin reduced visceral adipose tissue (VAT) by 15.2% over 26 weeks in HIV-lipodystrophy patients. A result attributable to its selective GHRH receptor agonism rather than broad ghrelin pathway activation. That distinction matters because GHRP-2 acetate, despite producing comparable IGF-1 elevation, operates through an entirely different mechanism: ghrelin receptor (GHS-R1a) binding that triggers pulsatile growth hormone release without the receptor specificity tesamorelin demonstrates.
- Our team has worked with researchers evaluating both peptides across metabolic studies. The gap between choosing GHRP-2 acetate vs tesamorelin which better comparison comes down to three factors most peptide guides ignore: receptor pathway selectivity, cortisol co-release potential, and tissue-specific fat mobilisation patterns.
- What's the primary difference between GHRP-2 acetate and tesamorelin for growth hormone elevation?
- GHRP-2 acetate binds ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus to stimulate pulsatile GH release, often with concurrent cortisol and prolactin elevation. Tesamorelin functions as a GHRH analogue, selectively activating GHRH receptors to increase endogenous GH without significant cortisol co-secretion. Clinical trials show tesamorelin reduces visceral fat 15–18% over six months in lipodystrophy populations, while GHRP-2 demonstrates broader anabolic effects across muscle and bone tissue but with higher adrenal axis activation risk.
- Yes, both peptides elevate IGF-1 and improve body composition metrics. But not through identical pathways. GHRP-2 acetate triggers GH secretion via ghrelin receptor mimicry, activating downstream signalling cascades that affect appetite, cortisol, and prolactin alongside growth hormone. Tesamorelin bypasses ghrelin entirely, binding GHRH receptors to selectively stimulate somatotrophs in the anterior pituitary. Producing GH release with minimal impact on cortisol or feeding behaviour. The rest of this piece covers exactly how those receptor differences translate to practical research outcomes, what dosing protocols clinical data supports, and which peptide aligns with specific metabolic or anabolic research objectives.